{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:10Z","timestamp":1786991230403,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"AHA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011912","name":"School of Medicine, Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK052574"],"award-info":[{"award-number":["P30DK052574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacadv.2025.101839","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:17:12Z","timestamp":1750864632000},"page":"101839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["Sodium-Glucose Cotransporter Inhibition Preserves Apolipoprotein M During Acute Inflammation in Mice and Humans"],"prefix":"10.1016","volume":"4","author":[{"given":"Carla","family":"Valenzuela Ripoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aynaz","family":"Lotfinaghsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-4852","authenticated-orcid":false,"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana N.","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Sargazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mualla","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Ataran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Hajirezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonje","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Weinheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kozyraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oscarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Esterline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-0097","authenticated-orcid":false,"given":"Justin H.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra S.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-978X","authenticated-orcid":false,"given":"Luigi","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-7514","authenticated-orcid":false,"given":"Charlie","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Javaheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.101839_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","article-title":"Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF","volume":"142","author":"Docherty","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101839_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101839_bib3","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of Life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101839_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101839_bib6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehab094","article-title":"Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial","volume":"42","author":"Heerspink","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2025.101839_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10787-020-00732-4","article-title":"Empagliflozin suppresses inflammation and protects against acute septic renal injury","volume":"29","author":"Maayah","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jacadv.2025.101839_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-8587(23)00253-X","article-title":"Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"11","author":"Group","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101839_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101839_bib10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S2213-8587(24)00218-3","article-title":"Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101839_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2024.10510","article-title":"Dapagliflozin for critically Ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial","volume":"332","author":"Tavares","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2025.101839_bib12","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2025.101839_bib13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00210-023-02685-1","article-title":"Sodium-glucose cotransporter-2 inhibitor in risk of sepsis\/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data","volume":"397","author":"Hu","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jacadv.2025.101839_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacadv.2025.101839_bib15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/cpt.3194","article-title":"SGLT-2 inhibitor use and cause-specific hospitalization rates: an outcome-wide study to identify novel associations of SGLT-2 inhibitors","volume":"115","author":"Tan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacadv.2025.101839_bib16","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1096\/fj.201500064","article-title":"Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1","volume":"30","author":"Christensen","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.jacadv.2025.101839_bib17","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacadv.2025.101839_bib18","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/jcmm.12831","article-title":"Sphingosine 1-phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons","volume":"20","author":"Frej","year":"2016","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/ATVBAHA.116.308435","article-title":"High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1","volume":"37","author":"Ruiz","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacadv.2025.101839_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/00365510600885500","article-title":"Progress in understanding its regulation and metabolic functions","volume":"66","author":"Christoffersen","year":"2006","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jacadv.2025.101839_bib21","doi-asserted-by":"crossref","first-page":"31286","DOI":"10.1074\/jbc.274.44.31286","article-title":"A novel human apolipoprotein (apoM)","volume":"274","author":"Xu","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101839_bib22","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1074\/jbc.M113.499913","article-title":"Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM\/sphingosine 1-phosphate-enriched plasma high density lipoprotein","volume":"289","author":"Liu","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101839_bib23","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1194\/jlr.M600055-JLR200","article-title":"Isolation and characterization of human apolipoprotein M-containing lipoproteins","volume":"47","author":"Christoffersen","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacadv.2025.101839_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.846990","article-title":"HDL composition, heart failure, and its comorbidities","volume":"9","author":"Diab","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib25","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.045323","article-title":"Reduced apolipoprotein M and adverse outcomes across the spectrum of human heart failure","volume":"141","author":"Chirinos","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101839_bib26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1194\/jlr.P089409","article-title":"Plasma apoM and S1P levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus","volume":"60","author":"Liu","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacadv.2025.101839_bib27","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013424","article-title":"Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19","volume":"13","author":"Marfia","year":"2021","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2007.10.007","article-title":"Infection and inflammation decrease apolipoprotein M expression","volume":"199","author":"Feingold","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101839_bib29","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/cc11305","article-title":"Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes","volume":"16","author":"Kumaraswamy","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jacadv.2025.101839_bib30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1055\/s-0038-1641750","article-title":"Apolipoprotein M protects lipopolysaccharide-treated mice from death and organ injury","volume":"118","author":"Kurano","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacadv.2025.101839_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adh0185","article-title":"High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response","volume":"16","author":"Mi","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib32","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib33","doi-asserted-by":"crossref","first-page":"17262","DOI":"10.1074\/jbc.M115.660084","article-title":"Generation of a potent low density lipoprotein receptor-related protein 1 (LRP1) antagonist by engineering a stable form of the receptor-associated protein (RAP) D3 domain","volume":"290","author":"Prasad","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101839_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nmeth.3322","article-title":"Catchup: a mouse model for imaging-based tracking and modulation of neutrophil granulocytes","volume":"12","author":"Hasenberg","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.jacadv.2025.101839_bib35","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1073\/pnas.1310653110","article-title":"Differentiated kidney epithelial cells repair injured proximal tubule","volume":"111","author":"Kusaba","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacadv.2025.101839_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1096\/fj.02-0578fje","article-title":"Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect","volume":"17","author":"Leheste","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.jacadv.2025.101839_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010866","article-title":"Transcription factor EB activation rescues advanced alphaB-crystallin mutation-induced cardiomyopathy by normalizing desmin localization","volume":"8","author":"Ma","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.101839_bib38","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2337\/db20-0591","article-title":"Toll-like receptor 2 (TLR2) knockout abrogates diabetic and obese phenotypes while restoring endothelial function via inhibition of NOX1","volume":"70","author":"Guo","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.jacadv.2025.101839_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2017.08.005","article-title":"Effects of apolipoprotein M in uremic atherosclerosis","volume":"265","author":"Bosteen","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacadv.2025.101839_bib40","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211083","article-title":"Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation","volume":"219","author":"Li","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib41","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/S0026-0495(98)90304-3","article-title":"Differential effects of fat and sucrose on body composition in A\/J and C57BL\/6 mice","volume":"47","author":"Black","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.jacadv.2025.101839_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00125-005-1680-z","article-title":"A genetic and physiological study of impaired glucose homeostasis control in C57BL\/6J mice","volume":"48","author":"Toye","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacadv.2025.101839_bib43","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20188793","article-title":"Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease","volume":"15","author":"Niu","year":"2019","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.jacadv.2025.101839_bib44","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa433","article-title":"Apolipoprotein M and risk of type 2 diabetes","volume":"105","author":"Hajny","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2025.101839_bib45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacbts.2022.09.010","article-title":"Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury","volume":"8","author":"Guo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacadv.2025.101839_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41419-022-04674-3","article-title":"Plasma proteomic and metabolomic characterization of COVID-19 survivors 6 months after discharge","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jacadv.2025.101839_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2020.05.032","article-title":"Proteomic and metabolomic characterization of COVID-19 patient sera","volume":"182","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jacadv.2025.101839_bib48","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jacl.2021.10.005","article-title":"HDL proteome remodeling associates with COVID-19 severity","volume":"15","author":"Souza Junior","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacadv.2025.101839_bib49","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1074\/jbc.M114.596445","article-title":"LDL receptor and ApoE are involved in the clearance of ApoM-associated sphingosine 1-phosphate","volume":"290","author":"Kurano","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101839_bib50","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1210\/me.2005-0209","article-title":"Megalin is a receptor for apolipoprotein M, and kidney-specific megalin-deficiency confers urinary excretion of apolipoprotein M","volume":"20","author":"Faber","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101839_bib51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbrc.2011.02.118","article-title":"Megalin is downregulated via LPS-TNF-alpha-ERK1\/2 signaling pathway in proximal tubule cells","volume":"407","author":"Takeyama","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacadv.2025.101839_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ki.2012.62","article-title":"Acute endotoxemia in mice induces downregulation of megalin and cubilin in the kidney","volume":"82","author":"Schreiber","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacadv.2025.101839_bib53","doi-asserted-by":"crossref","first-page":"11388","DOI":"10.1074\/jbc.RA117.001337","article-title":"High glucose reduces megalin-mediated albumin endocytosis in renal proximal tubule cells through protein kinase B O-GlcNAcylation","volume":"293","author":"Peruchetti","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101839_bib54","doi-asserted-by":"crossref","first-page":"18765","DOI":"10.1074\/jbc.M800695200","article-title":"The signal peptide anchors apolipoprotein M in plasma lipoproteins and prevents rapid clearance of apolipoprotein M from plasma","volume":"283","author":"Christoffersen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacadv.2025.101839_bib55","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib56","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2025.101839_bib57","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.40558","article-title":"Sphingosine 1-phosphate receptor 1 signaling maintains endothelial cell barrier function and protects against immune complex-induced vascular injury","volume":"70","author":"Burg","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacadv.2025.101839_bib58","doi-asserted-by":"crossref","first-page":"ra79","DOI":"10.1126\/scisignal.aaa2581","article-title":"HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation","volume":"8","author":"Galvani","year":"2015","journal-title":"Sci Signal"},{"key":"10.1016\/j.jacadv.2025.101839_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacadv.2025.101839_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154405","article-title":"Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy","volume":"113","author":"Otomo","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jacadv.2025.101839_bib61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacadv.2025.101839_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101367","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","author":"Wu","year":"2022","journal-title":"Diabetes Metab"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25002583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25002583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:32:57Z","timestamp":1778934777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25002583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2772963X25002583"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101839","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter Inhibition Preserves Apolipoprotein M During Acute Inflammation in Mice and Humans","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101839"}}